| Allison Judeen Decurtins, CNP | |
|
311 W Cottonwood St, Arlington, SD 57212-2016 | |
| (605) 270-1534 | |
| Not Available |
| Full Name | Allison Judeen Decurtins |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 4 Years |
| Location | 311 W Cottonwood St, Arlington, South Dakota |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1497363113 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363L00000X | Nurse Practitioner | CP001789 (South Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Prairie Lakes Healthcare System, Inc | Watertown, SD | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Simply Gorgeous Llc | 8022483254 | 2 |
| T And L Quick Care Pc | 1153670120 | 8 |
News Archive
Dutch researcher Joost Wiersinga from AMC Medical Centre in Amsterdam has unravelled a genetic defence mechanism against the lethal bacteria Burkholderia pseudomallei. The research is the next step towards a vaccine against this bacterium suitable for bioweapons.
Inova Translational Medicine Institute and Personalis, Inc. today announced a partnership to advance genomic medicine for Inova's patient population.
A team lead by Cancer Research UK scientists have shown that a potential new drug could treat mixed-lineage leukaemia (MLL), the most common form of leukaemia in babies, according to a study published in Nature today.
VIVUS, Inc. today announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting.
› Verified 9 days ago
| Entity Name | T & L Quick Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437650751 PECOS PAC ID: 1153670120 Enrollment ID: O20180823003741 |
News Archive
Dutch researcher Joost Wiersinga from AMC Medical Centre in Amsterdam has unravelled a genetic defence mechanism against the lethal bacteria Burkholderia pseudomallei. The research is the next step towards a vaccine against this bacterium suitable for bioweapons.
Inova Translational Medicine Institute and Personalis, Inc. today announced a partnership to advance genomic medicine for Inova's patient population.
A team lead by Cancer Research UK scientists have shown that a potential new drug could treat mixed-lineage leukaemia (MLL), the most common form of leukaemia in babies, according to a study published in Nature today.
VIVUS, Inc. today announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting.
› Verified 9 days ago
| Entity Name | American Advanced Practice Network Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790244341 PECOS PAC ID: 0749517860 Enrollment ID: O20190830001647 |
News Archive
Dutch researcher Joost Wiersinga from AMC Medical Centre in Amsterdam has unravelled a genetic defence mechanism against the lethal bacteria Burkholderia pseudomallei. The research is the next step towards a vaccine against this bacterium suitable for bioweapons.
Inova Translational Medicine Institute and Personalis, Inc. today announced a partnership to advance genomic medicine for Inova's patient population.
A team lead by Cancer Research UK scientists have shown that a potential new drug could treat mixed-lineage leukaemia (MLL), the most common form of leukaemia in babies, according to a study published in Nature today.
VIVUS, Inc. today announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting.
› Verified 9 days ago
| Entity Name | Simply Gorgeous Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750092151 PECOS PAC ID: 8022483254 Enrollment ID: O20230331000661 |
News Archive
Dutch researcher Joost Wiersinga from AMC Medical Centre in Amsterdam has unravelled a genetic defence mechanism against the lethal bacteria Burkholderia pseudomallei. The research is the next step towards a vaccine against this bacterium suitable for bioweapons.
Inova Translational Medicine Institute and Personalis, Inc. today announced a partnership to advance genomic medicine for Inova's patient population.
A team lead by Cancer Research UK scientists have shown that a potential new drug could treat mixed-lineage leukaemia (MLL), the most common form of leukaemia in babies, according to a study published in Nature today.
VIVUS, Inc. today announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Allison Judeen Decurtins, CNP 311 W Cottonwood St, Arlington, SD 57212-2016 Ph: (605) 270-1534 | Allison Judeen Decurtins, CNP 311 W Cottonwood St, Arlington, SD 57212-2016 Ph: (605) 270-1534 |
News Archive
Dutch researcher Joost Wiersinga from AMC Medical Centre in Amsterdam has unravelled a genetic defence mechanism against the lethal bacteria Burkholderia pseudomallei. The research is the next step towards a vaccine against this bacterium suitable for bioweapons.
Inova Translational Medicine Institute and Personalis, Inc. today announced a partnership to advance genomic medicine for Inova's patient population.
A team lead by Cancer Research UK scientists have shown that a potential new drug could treat mixed-lineage leukaemia (MLL), the most common form of leukaemia in babies, according to a study published in Nature today.
VIVUS, Inc. today announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting.
› Verified 9 days ago
Mandy L Wilde, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 104 W Birch St, Arlington, SD 57212 Phone: 605-983-3283 Fax: 605-983-5112 |